PRTO PROTEON THERAPEUTICS

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Proteon Therapeutics, Inc.

NEW YORK--(BUSINESS WIRE)--

Levi & Korsinsky announces it has commenced an investigation of Proteon Therapeutics, Inc. (NASDAQ:PRTO) concerning possible violations of federal securities laws. The investigation concerns whether Proteon made materially false and/or misleading statements and/or failed to disclose material information regarding its product candidate vonapanitase. Despite positive statements made regarding the efficacy and potential FDA approval of the drug, on December 13, 2016, Proteon announced that vonapanitase did not meet its primary endpoint in its first Phase 3 PATENCY-1 clinical trial. Following this news, shares of Proteon Therapeutics fell approximately 75% to close at $2.50 on December 12, 2016. To obtain additional information, go to:

http://zlk.9nl.com/proteon-therapeutics-prto

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
23/03/2017

Underlying

PRTOPROTEON THERAPEUTICS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PROTEON THERAPEUTICS

 PRESS RELEASE
Free
PRTO PROTEON THERAPE...

Proteon Therapeutics Announces Third Quarter 2019 Financial Results

Proteon Therapeutics Announces Third Quarter 2019 Financial Results WALTHAM, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- (“Proteon” or the “Company”) (Nasdaq: PRTO), a company that has historically focused on the development of novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular disease, today announced its financial results for the quarter ended September 30, 2019, and recent events.  Recent Events Signing of Definitive Merger Agreement Announced. On September 23, 2019, Proteon announced it had entered into a definitive agreement in whi...

October 31, 2019 1 EN
 PRESS RELEASE
Free
PRTO PROTEON THERAPE...

Proteon Therapeutics and ArTara Therapeutics Agree to Combine

Proteon Therapeutics and ArTara Therapeutics Agree to Combine Transaction to Create NASDAQ-Listed Rare and Specialty Disease Therapeutic Company Focused on Immunology and Metabolic Disorders $42.5M Concurrent Financing to be Led by a Syndicate of Healthcare Dedicated Investors Companies to Hold Conference Call on September 24th at 8:30AM EDT WALTHAM, Mass. and  NEW YORK, Sept. 23, 2019 (GLOBE NEWSWIRE) -- (“Proteon”) (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, and (“ArTara”), a ...

September 23, 2019 1 EN
 PRESS RELEASE
Free
PRTO PROTEON THERAPE...

Proteon Therapeutics Announces Second Quarter 2019 Financial Results

Proteon Therapeutics Announces Second Quarter 2019 Financial Results WALTHAM, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- (Nasdaq: PRTO), a company that has historically focused on the development of novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular disease, today announced its financial results for the quarter ended June 30, 2019, and recent events.  Recent Events Engaged H.C. Wainwright to Assist in Strategic Review. On April 15, 2019, Proteon announced it had engaged H.C. Wainwright & Co., LLC as its financial advisor to assist in t...

August 7, 2019 1 EN
 PRESS RELEASE
Free
PRTO PROTEON THERAPE...

Proteon Therapeutics Announces First Quarter 2019 Financial Results

Proteon Therapeutics Announces First Quarter 2019 Financial Results WALTHAM, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, today announced its financial results for the quarter ended March 31, 2019, and recent events.  Recent Events PATENCY-2 Trial Misses Statistical Significance on Both Co-Primary Endpoints. On March 28, 2019, the Company announced top-line results from PATENCY-2, its Phase 3 clinical trial of investigational vonapanitase...

May 8, 2019 1 EN
 PRESS RELEASE
Free
PRTO PROTEON THERAPE...

Proteon Therapeutics Announces Review of Potential Strategic Transacti...

Proteon Therapeutics Announces Review of Potential Strategic Transactions WALTHAM, Mass., April 15, 2019 (GLOBE NEWSWIRE) -- (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, today announced its plans to explore a range of strategic options to enhance shareholder value. Having missed statistical significance on both co-primary endpoints in PATENCY-2, Proteon’s second Phase 3 trial of investigational vonapanitase, the Board of Directors has decided to explore all strategic alternatives fo...

April 15, 2019 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch